We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Summit Therapeutics Plc | LSE:SUMM | London | Ordinary Share | GB00BN40HZ01 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 20.50 | 18.00 | 23.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
26/7/2018 08:50 | Down on no volume,go figure! | the canadian mounted | |
26/7/2018 06:43 | Not that it's of much interest anymore... | waterloo01 | |
25/7/2018 20:40 | If you're crowdfunding the report Football then please put me down for a Fiver. Anyone else in? | algernon2 | |
25/7/2018 19:36 | anyone got $3500 to have a look | football | |
25/7/2018 18:09 | Another 200K in after close. Looks like a corporate firm hedging their position. They do not hedge position if they do not think it could reverse. | exotic matter | |
25/7/2018 17:41 | Looks more like some kind of rollover to me. | dan1nat1 | |
25/7/2018 16:08 | Surprised this has dropped on the volume of buys | the canadian mounted | |
25/7/2018 13:01 | Now the dust has settled a slow steady climb will reward the patient investors. | the canadian mounted | |
25/7/2018 11:39 | Assume the 200k shares at 38p was a worked buy. ANO director purchase? | waterloo01 | |
25/7/2018 07:36 | This will come good,patience needed. | the canadian mounted | |
23/7/2018 17:52 | Let's hope it is soon !! | kirk 6 | |
23/7/2018 17:48 | when it's up 80% i might feel abit better gla | football | |
23/7/2018 17:46 | Bloody hell spiked up 8% then | kirk 6 | |
23/7/2018 17:12 | Again heading up on the Nasdaq | kirk 6 | |
21/7/2018 11:55 | Water agreed especially with he amount of director buying as well .Fair value 70p I would say | kirk 6 | |
21/7/2018 09:58 | Up 8% on Nasdaq. With the market cap in cash, I'm tempted to say that there is limited downside from here (famous last words?) | waterloo01 | |
20/7/2018 23:42 | A pure diagnostics paper, Chris, so no mention of drugs for resistant disease. Summit are in a strong position to develop companion diagnostics given their expertise. Adds value. | freedosh | |
20/7/2018 18:42 | Resistance to Gonorrhea Spurs Bespoke Treatments Researchers are developing diagnostics to determine which drugs might work for specific patients Edit: Not just us but no mention of Summit | chrisatrdg | |
19/7/2018 19:56 | I agree Waterloo ... for us long term investors, it's a question of trying to raise enough funds to buy in whilst the share price is so low, in order to get our average share price low enough to just recover our losses. | hugus maximus | |
19/7/2018 12:33 | I wonder if the person who sent them is no longer with the company? I take today's share purchases as a positive. I know they had to exersize them and at 1p but I would have expected more to have sold a portion to cover costs, but didn't. Again tells me they also know the value is there and will be realised. | waterloo01 | |
19/7/2018 09:10 | I have not received RNS's recently. | chrisatrdg | |
19/7/2018 08:57 | I no longer receive SUMM RNS reports ... are you all receiving email updates? | hugus maximus | |
19/7/2018 07:15 | RNS Today: Exercise of Restricted Stock Units and Director Dealings Edit: I am surprised that considering the severe drop in share price & the huge losses we have all incurred that the Directors can get such a bargain today.It does not seem fair or are they getting in before the axe falls.Hey ho. | chrisatrdg | |
18/7/2018 11:11 | I wish I had known Mellon's tactics earlier I now have more shares than his company.I wish I had asked him when I bumped into him at the James Comey event a few weeks back at the Barbican. | chrisatrdg |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions